A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer

Clin Colorectal Cancer. 2006 Jan;5(5):363-7. doi: 10.3816/CCC.2006.n.008.

Authors

Zev Wainberg¹, J Randolph Hecht

Affiliation

¹ GI Oncology Program, David Geffen School of Medicine, University of California, Los Angeles 90095, USA.

PMID: 16512997
DOI: 10.3816/CCC.2006.n.008

No abstract available

MeSH terms

Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Bevacizumab
Clinical Trials, Phase III as Topic
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / secondary*
Humans
Immunologic Factors / administration & dosage*
Panitumumab
Randomized Controlled Trials as Topic

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Immunologic Factors
Bevacizumab
Panitumumab